| 0I3 Stock | | | EUR 63.50 0.00 0.00% |
CTO
Guangqiang Jiang is Chief Technology Officer of Axonics since 2015.
| Age | 49 |
| Tenure | 9 years |
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
Axonics Management Efficiency
The company has return on total asset
(ROA) of
(0.0624) % which means that it has lost $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.1453) %, meaning that it generated substantial loss on money invested by shareholders. Axonics' management efficiency ratios could be used to measure how well Axonics manages its routine affairs as well as how well it operates its assets and liabilities.
Axonics has accumulated 10.01
M in total debt with debt to equity ratio
(D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics has a current ratio of 13.35, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Axonics until it has trouble settling it off, either with new capital or with free cash flow. So, Axonics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axonics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axonics to invest in growth at high rates of return. When we think about Axonics' use of debt, we should always consider it together with cash and equity.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation systems. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California. AXONICS INC operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 416 people. Axonics (0I3) is traded on Frankfurt Exchange in Germany and employs 517 people.
Management Performance
Axonics Leadership Team
Elected by the shareholders, the Axonics' board of directors comprises two types of representatives: Axonics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics' management team and ensure that shareholders' interests are well served. Axonics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Amble, Independent Director | |
| Jane Kiernan, Independent Director | |
| MD MAS, Chief Officer | |
| Raymond Cohen, Chief Executive Officer, Director | |
| Karen Noblett, Chief Medical Officer | |
| JD Esq, Gen VP | |
| John Woock, Chief Marketing Officer | |
| Neil Bhalodkar, VP Relations | |
| Nancy Snyderman, Independent Director | |
| Robert McNamara, Independent Director | |
| Alfred Ford, Chief Commercial Officer | |
| Michael Carrel, Independent Chairman of the Board | |
| Dan Dearen, President, Chief Financial Officer | |
| Danny Dearen, Pres CFO | |
| Rinda Sama, Chief Operating Officer | |
| Juliet Bakker, Independent Director | |
| Aaron Pettit, G Officer | |
| David Demski, Director | |
| Prabodh Mathur, Chief Product Development Officer | |
| Guangqiang Jiang, Chief Technology Officer | |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Axonics Stock
Axonics financial ratios help investors to determine whether Axonics Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axonics with respect to the benefits of owning Axonics security.